Literature DB >> 33864519

Immunohistochemical localization and pharmacokinetics of the anti-MRSA drug teicoplanin in rat kidney using a newly developed specific antibody.

Yutaro Yamamoto1, Yuta Yamamoto1, Tetsuya Saita1, Masashi Shin2.   

Abstract

We prepared a polyclonal antibody against a teicoplanin (TEIC)-bovine serum albumin conjugate that was specific to both conjugated and free forms of TEIC. We demonstrated that this antibody could be used to detect the time-dependent localization of TEIC in rat kidneys. Immunohistochemistry revealed immunoreactivity specifically in the microvilli and apical cytoplasm of epithelial cells in proximal tubule segments S1 and S2, 1 h after intravenous TEIC injection, with higher staining intensity in the S2 segments. The epithelial cells of S3 segments showed moderate immunostaining with a few cells exhibiting nuclear staining. Furthermore, we found that the distal tubules and collecting ducts contained both TEIC-positive and -negative cells. TEIC immunoreactivity decreased rapidly over time; only weak staining remained in the S3 segments, distal tubules, and collecting ducts 24 h after administration. No staining was detected 7 days after injection. These results were significantly different from those of our previous study obtained using vancomycin, which showed moderate staining in the proximal tubule segments S1 and S2, distal tubules, and the collecting ducts 8 days after administration. The lower TEIC accumulation in tissues may account for a lower risk of adverse events compared to that using vancomycin.
© 2021. The Japanese Society for Clinical Molecular Morphology.

Entities:  

Keywords:  Adverse event; Immunohistochemistry; Kidney; Pharmacokinetics; Teicoplanin

Mesh:

Substances:

Year:  2021        PMID: 33864519     DOI: 10.1007/s00795-021-00286-6

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  1 in total

1.  Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma.

Authors:  Izumi Shimada; Chieko Iwata; Shino Taga; Hitomi Teramachi; Masaaki Nomura; Ken-Ichi Miyamoto; Hiroyuki Tsuciya; Takashi Wada; Kazuko Kimura; Ryo Matsushita
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

  1 in total
  1 in total

1.  Development of immunohistochemistry for detecting fluvoxamine in rat tissues using newly prepared monoclonal antibody: its precise localization in small intestine, kidney, and liver of rats.

Authors:  Masashi Shin; Yutaro Yamamoto; Hiroto Kataoka; Tetsuya Saita
Journal:  Med Mol Morphol       Date:  2022-10-11       Impact factor: 2.070

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.